Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus

Area of Science:

• Rheumatology
• Immunology

Background:

• Organ damage significantly impacts long-term prognosis and survival in systemic lupus erythematosus (SLE).
• Preventing organ damage is a primary objective in SLE management, as highlighted by the 2019 EULAR recommendations.
• Belimumab, a B lymphocyte stimulator (BLyS)-inhibiting monoclonal antibody, is approved for SLE and lupus nephritis.

Purpose of the Study:

• To review clinical trial and real-world data on belimumab's effects on organ damage in adult SLE patients.
• To assess belimumab's impact on disease activity, flares, glucocorticoid use, and organ damage progression.

Main Methods:

• Analysis of data from four phase III studies of belimumab in SLE.
• Review of open-label extension studies and propensity score-matched comparative analyses.
• Evaluation of a clinical trial focused on belimumab in active lupus nephritis.

Main Results:

• Belimumab, with background therapy, consistently reduced SLE disease activity, new severe flares, and glucocorticoid exposure.
• Long-term belimumab use demonstrated reduced organ damage progression (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index).
• In lupus nephritis, belimumab improved renal response, reduced renal events, and impacted kidney damage progression.

Conclusions:

• Belimumab treatment in SLE, including lupus nephritis, is associated with decreased organ damage accumulation.
• These findings suggest a potential disease-modifying effect of belimumab in SLE.
• Belimumab offers a therapeutic option to mitigate organ damage and improve outcomes in SLE patients.